Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Kite, Shoreline Biosciences in pact to develop novel allogeneic cell therapies » 09:06
06/17/21
06/17
09:06
06/17/21
09:06
GILD

Gilead

$67.33 /

-0.78 (-1.15%)

Kite, a Gilead Company …

Kite, a Gilead Company and Shoreline Biosciences, Inc. announced a strategic partnership to develop novel cell therapies across a variety of cancer targets. The collaboration will leverage Shoreline's deep expertise in iPSC differentiation and genetic reprogramming in combination with Kite's extensive cell therapy development, commercialization and manufacturing expertise to develop novel allogeneic candidates for a range of hematologic malignancies. The collaboration will focus initially on chimeric antigen receptor (CAR) NK targets, with Kite having an option to expand the collaboration to include an iPSC CAR Macrophage program for an undisclosed target to be selected post deal execution. This agreement follows Kite's investment in Shoreline's recent Series A financing. "As the leader in cell therapy, we are focused on investing in and delivering on the most promising opportunities to further optimize the therapeutic potential of cell therapy," said Mert Aktar, Vice President of Corporate Development and Strategy at Kite. "We are excited about the potential of Shoreline's next-generation approach to allogeneic development, and how our collaboration can accelerate this research across different leukemias and lymphomas."

ShowHide Related Items >><<
GILD Gilead
$67.33 /

-0.78 (-1.15%)

GILD Gilead
$67.33 /

-0.78 (-1.15%)

06/16/21 Roth Capital
JTX-1811 IND-clearance further validates Jounce platform, says Roth Capital
06/15/21 Piper Sandler
Jounce Therapeutics receives $25M milestone from Gilead, says Piper Sandler
04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
GILD Gilead
$67.33 /

-0.78 (-1.15%)

GILD Gilead
$67.33 /

-0.78 (-1.15%)

GILD Gilead
$67.33 /

-0.78 (-1.15%)

GILD Gilead
$67.33 /

-0.78 (-1.15%)

Hot Stocks
Canadian National to invest C$350M in Ontario, C$95M in Manitoba » 08:12
06/17/21
06/17
08:12
06/17/21
08:12
CNI

Canadian National

$107.97 /

-2.25 (-2.04%)

CN announces plans to…

CN announces plans to invest approximately C$350M in Ontario in 2021 as part of CN's C$3B capital investment plan across its network. In Ontario, CN's investment will focus on technology, capacity, and infrastructure maintenance to enhance safety and the fluidity of its network. CN also announces plans to invest approximately C$95M in Manitoba in 2021 as part of CN's C$3B capital investment plan across its network. In Manitoba, CN's investment will focus on technology, and infrastructure maintenance to enhance safety and the fluidity of its network. "Our consistent and proactive infrastructure investment strategy and the essential work of our employees and supply chain partners are what enable CN to keep the economy moving safely and smoothly year after year. Safety is a core value at CN and we will continue to invest in our track and in technology to support our overall network capacity and provide our customers with safe and reliable service. As we look to the future, we are excited about the opportunity to do even more for our customers, employees, communities and shareholders through our end-to-end, pro-competitive combination with Kansas City Southern, which will connect North America and build the premier railway for the 21st Century."

ShowHide Related Items >><<
CNI Canadian National
$107.97 /

-2.25 (-2.04%)

CNI Canadian National
$107.97 /

-2.25 (-2.04%)

05/28/21 UBS
Canadian National upgraded to Buy from Neutral at UBS
05/28/21 Barclays
Kansas City Southern downgraded to Underweight from Equal Weight at Barclays
05/27/21 Scotiabank
Canadian Pacific price target raised to C$108 from C$96 at Scotiabank
05/27/21 Scotiabank
Canadian National upgraded to Outperform at Scotiabank after 12% pullback
CNI Canadian National
$107.97 /

-2.25 (-2.04%)

CNI Canadian National
$107.97 /

-2.25 (-2.04%)

CNI Canadian National
$107.97 /

-2.25 (-2.04%)

CNI Canadian National
$107.97 /

-2.25 (-2.04%)

Conference/Events
European Hematology Association to hold virtual meeting » 04:55
06/17/21
06/17
04:55
06/17/21
04:55
APTO

Aptose Biosciences

$3.39 /

-0.115 (-3.29%)

, MBIO

Mustang Bio

$3.48 /

-0.09 (-2.52%)

, QURE

uniQure

$34.41 /

-0.015 (-0.04%)

, RIGL

Rigel Pharmaceuticals

$4.20 /

-0.07 (-1.64%)

, MGTA

Magenta Therapeutics

$11.13 /

-0.2 (-1.77%)

, MEIP

MEI Pharma

$3.32 /

+0.22 (+7.10%)

, CRIS

Curis

$7.58 /

-0.07 (-0.92%)

, XLRN

Acceleron

$126.85 /

-1.78 (-1.38%)

, EPZM

Epizyme

$8.81 /

+0.025 (+0.28%)

, INCY

Incyte

$83.13 /

+0.44 (+0.53%)

, ORTX

Orchard Therapeutics

$4.79 /

-0.06 (-1.24%)

, TGTX

TG Therapeutics

$36.64 /

-0.8 (-2.14%)

, EQ

Equillium

$5.87 /

-0.17 (-2.81%)

, JAZZ

Jazz Pharmaceuticals

$181.08 /

-2.19 (-1.19%)

, VRTX

Vertex Pharmaceuticals

$187.51 /

-1.43 (-0.76%)

, SGEN

Seagen

$151.42 /

-1.93 (-1.26%)

, IMRA

Imara

$7.76 /

-0.5 (-6.05%)

, GBT

Global Blood Therapeutics

$38.21 /

-1.39 (-3.51%)

, BGNE

BeiGene

$333.73 /

+2.27 (+0.68%)

, APLS

Apellis

$59.71 /

-0.97 (-1.60%)

, AGIO

Agios Pharmaceuticals

$58.82 /

+0.63 (+1.08%)

, FMTX

Forma Therapeutics

$24.23 /

+0.1 (+0.41%)

, KROS

Keros Therapeutics

$52.91 /

+0.32 (+0.61%)

, CYAD

Celyad

$5.33 /

-0.11 (-2.02%)

, ALXN

Alexion

$180.56 /

-1.34 (-0.74%)

EHA 2021 Virtual Congress…

EHA 2021 Virtual Congress to be held on June 9-17. Webcast Link

ShowHide Related Items >><<
XLRN Acceleron
$126.85 /

-1.78 (-1.38%)

VRTX Vertex Pharmaceuticals
$187.51 /

-1.43 (-0.76%)

TGTX TG Therapeutics
$36.64 /

-0.8 (-2.14%)

SGEN Seagen
$151.42 /

-1.93 (-1.26%)

RIGL Rigel Pharmaceuticals
$4.20 /

-0.07 (-1.64%)

QURE uniQure
$34.41 /

-0.015 (-0.04%)

ORTX Orchard Therapeutics
$4.79 /

-0.06 (-1.24%)

MGTA Magenta Therapeutics
$11.13 /

-0.2 (-1.77%)

MEIP MEI Pharma
$3.32 /

+0.22 (+7.10%)

MBIO Mustang Bio
$3.48 /

-0.09 (-2.52%)

KROS Keros Therapeutics
$52.91 /

+0.32 (+0.61%)

JAZZ Jazz Pharmaceuticals
$181.08 /

-2.19 (-1.19%)

INCY Incyte
$83.13 /

+0.44 (+0.53%)

IMRA Imara
$7.76 /

-0.5 (-6.05%)

GBT Global Blood Therapeutics
$38.21 /

-1.39 (-3.51%)

FMTX Forma Therapeutics
$24.23 /

+0.1 (+0.41%)

EQ Equillium
$5.87 /

-0.17 (-2.81%)

EPZM Epizyme
$8.81 /

+0.025 (+0.28%)

CYAD Celyad
$5.33 /

-0.11 (-2.02%)

CRIS Curis
$7.58 /

-0.07 (-0.92%)

BGNE BeiGene
$333.73 /

+2.27 (+0.68%)

APTO Aptose Biosciences
$3.39 /

-0.115 (-3.29%)

APLS Apellis
$59.71 /

-0.97 (-1.60%)

ALXN Alexion
$180.56 /

-1.34 (-0.74%)

AGIO Agios Pharmaceuticals
$58.82 /

+0.63 (+1.08%)

APTO Aptose Biosciences
$3.39 /

-0.115 (-3.29%)

02/22/21 JonesTrading
Aptose Biosciences resumed with a Buy at JonesTrading
10/19/20 Cantor Fitzgerald
Aptose Biosciences initiated with an Overweight at Cantor Fitzgerald
09/22/20 Alliance Global Partners
Aptose Biosciences initiated with a Buy at Alliance Global Partners
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
MBIO Mustang Bio
$3.48 /

-0.09 (-2.52%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
QURE uniQure
$34.41 /

-0.015 (-0.04%)

06/16/21 Chardan
uniQure on track for 'powerful' Huntington's catalyst, says Chardan
06/14/21 BTIG
uniQure initiated with a Buy at BTIG
05/20/21 UBS
uniQure initiated with a Neutral at UBS
05/19/21 H.C. Wainwright
uniQure price target raised to $90 from $80 at H.C. Wainwright
RIGL Rigel Pharmaceuticals
$4.20 /

-0.07 (-1.64%)

06/11/21 BMO Capital
Rigel Pharmaceuticals coverage transferred at BMO Capital
05/12/21 Cantor Fitzgerald
Rigel rallying on Curis IRAK4 program data, says Cantor Fitzgerald
04/13/21 Piper Sandler
Rigel results in severe COVID-19 trial 'pretty dramatic,' says Piper Sandler
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
MGTA Magenta Therapeutics
$11.13 /

-0.2 (-1.77%)

06/14/21 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
05/18/21 B. Riley
Magenta Therapeutics initiated with a Buy, $21 target at B. Riley
05/17/21 B. Riley
Magenta Therapeutics initiated with a Buy at B. Riley
05/13/21 Mizuho
Magenta Therapeutics price target raised to $17 from $16 at Mizuho
MEIP MEI Pharma
$3.32 /

+0.22 (+7.10%)

04/26/21 Wells Fargo
MEI Pharma likely to expand scope of voruciclib development, says Wells Fargo
10/12/20 Brookline
MEI Pharma initiated with a Buy at Brookline
09/22/20 Alliance Global Partners
MEI Pharma initiated with a Buy at Alliance Global Partners
07/06/20 Truist
MEI Pharma price target lowered to $12 from $16 at SunTrust
CRIS Curis
$7.58 /

-0.07 (-0.92%)

05/13/21 B. Riley
Curis price target raised to $22 from $19 at B. Riley
05/13/21 Cantor Fitzgerald
Curis price target raised to $24 from $15 at Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Initial look from Curis EHA updates 'very positive,' says Cantor Fitzgerald
XLRN Acceleron
$126.85 /

-1.78 (-1.38%)

06/11/21 H.C. Wainwright
Acceleron results for Phase 2 BEYOND study 'impressive,' says H.C. Wainwright
05/19/21 Piper Sandler
Piper remains bullish on Acceleron after Phase 2 PULSAR OLE, SPECTRA updates
04/26/21 Credit Suisse
Acceleron assumed with an Outperform at Credit Suisse
03/23/21
Fly Intel: Top five analyst downgrades
EPZM Epizyme
$8.81 /

+0.025 (+0.28%)

05/07/21 SVB Leerink
Epizyme upgraded to Outperform from Market Perform at SVB Leerink
04/23/21 Cowen
Epizyme transferred with Outperform at Cowen
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
INCY Incyte
$83.13 /

+0.44 (+0.53%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
ORTX Orchard Therapeutics
$4.79 /

-0.06 (-1.24%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/02/21 JPMorgan
Orchard Therapeutics assumed with an Overweight at JPMorgan
03/01/21 Stifel
Orchard Therapeutics initiated with a Buy at Stifel
02/18/21 Goldman Sachs
Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs
TGTX TG Therapeutics
$36.64 /

-0.8 (-2.14%)

04/20/21
Fly Intel: Top five analyst initiations
04/20/21 Goldman Sachs
TG Therapeutics initiated with a Neutral at Goldman Sachs
04/19/21 Cantor Fitzgerald
TG Therapeutics price target raised to $74 from $68 at Cantor Fitzgerald
04/19/21 H.C. Wainwright
TG Therapeutics price target raised to $89 from $79 at H.C. Wainwright
EQ Equillium
$5.87 /

-0.17 (-2.81%)

03/03/21
Fly Intel: Top five analyst initiations
03/03/21 JonesTrading
Equillium initiated with a Buy at JonesTrading
11/30/20 H.C. Wainwright
Equillium price target lowered to $12 from $22 at H.C. Wainwright
07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
JAZZ Jazz Pharmaceuticals
$181.08 /

-2.19 (-1.19%)

05/19/21
Fly Intel: Top five analyst initiations
05/19/21 JPMorgan
Jazz Pharmaceuticals resumed with an Overweight at JPMorgan
05/17/21 H.C. Wainwright
Jazz Pharmaceuticals price target raised to $212 from $207 at H.C. Wainwright
04/21/21 Cantor Fitzgerald
Jazz Pharmaceuticals price target raised to $198 from $185 at Cantor Fitzgerald
VRTX Vertex Pharmaceuticals
$187.51 /

-1.43 (-0.76%)

06/14/21 Truist
Vertex Pharmaceuticals price target raised to $331 from $305 at Truist
06/14/21 SVB Leerink
Vertex Pharmaceuticals price target lowered to $200 from $250 at SVB Leerink
06/14/21 Deutsche Bank
Grifols upgraded to Buy from Hold at Deutsche Bank
06/13/21 Piper Sandler
Vertex Pharmaceuticals price target lowered to $261 from $347 at Piper Sandler
SGEN Seagen
$151.42 /

-1.93 (-1.26%)

05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
IMRA Imara
$7.76 /

-0.5 (-6.05%)

03/08/21 SVB Leerink
Imara price target lowered to $42 from $59 at SVB Leerink
01/06/21 SVB Leerink
Imara selloff a potential buying opportunity, says SVB Leerink
08/17/20
Fly Intel: Top five analyst upgrades
08/17/20 Citi
Imara upgraded to Buy from Neutral at Citi
GBT Global Blood Therapeutics
$38.21 /

-1.39 (-3.51%)

05/07/21 Cantor Fitzgerald
Global Blood Therapeutics price target lowered to $110 from $120 at Cantor Fitzgerald
05/06/21 Piper Sandler
Global Blood price target lowered to $45 from $50 at Piper Sandler
04/14/21
Fly Intel: Top five analyst initiations
04/14/21 SVB Leerink
SVB Leerink bullish on Global Blood Therapeutics, initiates with an Outperform
BGNE BeiGene
$333.73 /

+2.27 (+0.68%)

06/14/21 SVB Leerink
BeiGene price target raised to $417 from $388 at SVB Leerink
03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
APLS Apellis
$59.71 /

-0.97 (-1.60%)

05/20/21 UBS
Apellis initiated with a Buy at UBS
05/18/21 BMO Capital
Apellis price target raised to $68 from $64 at BMO Capital
05/17/21 Oppenheimer
Apellis price target raised to $67 from $64 at Oppenheimer
05/17/21 Raymond James
Apellis price target raised to $115 from $104 at Raymond James
AGIO Agios Pharmaceuticals
$58.82 /

+0.63 (+1.08%)

06/10/21 H.C. Wainwright
Agios Pharmaceuticals initiated with a Buy at H.C. Wainwright
04/30/21 Goldman Sachs
Agios Pharmaceuticals reinstated with a Neutral at Goldman Sachs
04/30/21 Barclays
Agios Pharmaceuticals price target raised to $70 from $65 at Barclays
03/30/21 Piper Sandler
Agios should rally on Forma Therapeutics data, says Piper Sandler
FMTX Forma Therapeutics
$24.23 /

+0.1 (+0.41%)

03/31/21 H.C. Wainwright
Forma Therapeutics price target raised to $55 from $53 at H.C. Wainwright
02/17/21
Fly Intel: Top five analyst initiations
02/17/21 Oppenheimer
Forma Therapeutics initiated with an Outperform at Oppenheimer
KROS Keros Therapeutics
$52.91 /

+0.32 (+0.61%)

12/08/20 SVB Leerink
Keros Therapeutics price target raised to $80 from $42 at SVB Leerink
12/08/20 H.C. Wainwright
Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright
12/08/20 Piper Sandler
Keros Therapeutics price target raised to $95 from $75 at Piper Sandler
11/18/20 Piper Sandler
Keros Therapeutics price target raised to $75 from $55 at Piper Sandler
CYAD Celyad
$5.33 /

-0.11 (-2.02%)

03/25/21 JonesTrading
Celyad downgraded to Hold from Buy at JonesTrading
12/08/20 H.C. Wainwright
Celyad price target lowered to $18 from $22 at H.C. Wainwright
ALXN Alexion
$180.56 /

-1.34 (-0.74%)

05/05/21
Fly Intel: Top five analyst upgrades
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
05/03/21 SVB Leerink
Alexion price target raised to $173 from $156 at SVB Leerink
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
XLRN Acceleron
$126.85 /

-1.78 (-1.38%)

VRTX Vertex Pharmaceuticals
$187.51 /

-1.43 (-0.76%)

TGTX TG Therapeutics
$36.64 /

-0.8 (-2.14%)

SGEN Seagen
$151.42 /

-1.93 (-1.26%)

RIGL Rigel Pharmaceuticals
$4.20 /

-0.07 (-1.64%)

QURE uniQure
$34.41 /

-0.015 (-0.04%)

ORTX Orchard Therapeutics
$4.79 /

-0.06 (-1.24%)

MGTA Magenta Therapeutics
$11.13 /

-0.2 (-1.77%)

MEIP MEI Pharma
$3.32 /

+0.22 (+7.10%)

MBIO Mustang Bio
$3.48 /

-0.09 (-2.52%)

KROS Keros Therapeutics
$52.91 /

+0.32 (+0.61%)

JAZZ Jazz Pharmaceuticals
$181.08 /

-2.19 (-1.19%)

INCY Incyte
$83.13 /

+0.44 (+0.53%)

IMRA Imara
$7.76 /

-0.5 (-6.05%)

GBT Global Blood Therapeutics
$38.21 /

-1.39 (-3.51%)

FMTX Forma Therapeutics
$24.23 /

+0.1 (+0.41%)

EQ Equillium
$5.87 /

-0.17 (-2.81%)

EPZM Epizyme
$8.81 /

+0.025 (+0.28%)

CRIS Curis
$7.58 /

-0.07 (-0.92%)

BGNE BeiGene
$333.73 /

+2.27 (+0.68%)

APTO Aptose Biosciences
$3.39 /

-0.115 (-3.29%)

APLS Apellis
$59.71 /

-0.97 (-1.60%)

ALXN Alexion
$180.56 /

-1.34 (-0.74%)

AGIO Agios Pharmaceuticals
$58.82 /

+0.63 (+1.08%)

  • 15
    Dec
  • 09
    Dec
  • 11
    Dec
  • 02
    Dec
  • 13
    Nov
  • 14
    Aug
  • 16
    Jul
  • 01
    Jul
  • 25
    Jun
  • 19
    Jun
VRTX Vertex Pharmaceuticals
$187.51 /

-1.43 (-0.76%)

RIGL Rigel Pharmaceuticals
$4.20 /

-0.07 (-1.64%)

ORTX Orchard Therapeutics
$4.79 /

-0.06 (-1.24%)

JAZZ Jazz Pharmaceuticals
$181.08 /

-2.19 (-1.19%)

INCY Incyte
$83.13 /

+0.44 (+0.53%)

EPZM Epizyme
$8.81 /

+0.025 (+0.28%)

VRTX Vertex Pharmaceuticals
$187.51 /

-1.43 (-0.76%)

TGTX TG Therapeutics
$36.64 /

-0.8 (-2.14%)

SGEN Seagen
$151.42 /

-1.93 (-1.26%)

QURE uniQure
$34.41 /

-0.015 (-0.04%)

MBIO Mustang Bio
$3.48 /

-0.09 (-2.52%)

JAZZ Jazz Pharmaceuticals
$181.08 /

-2.19 (-1.19%)

INCY Incyte
$83.13 /

+0.44 (+0.53%)

IMRA Imara
$7.76 /

-0.5 (-6.05%)

GBT Global Blood Therapeutics
$38.21 /

-1.39 (-3.51%)

EQ Equillium
$5.87 /

-0.17 (-2.81%)

CRIS Curis
$7.58 /

-0.07 (-0.92%)

APTO Aptose Biosciences
$3.39 /

-0.115 (-3.29%)

APLS Apellis
$59.71 /

-0.97 (-1.60%)

ALXN Alexion
$180.56 /

-1.34 (-0.74%)

VRTX Vertex Pharmaceuticals
$187.51 /

-1.43 (-0.76%)

INCY Incyte
$83.13 /

+0.44 (+0.53%)

FMTX Forma Therapeutics
$24.23 /

+0.1 (+0.41%)

EQ Equillium
$5.87 /

-0.17 (-2.81%)

CRIS Curis
$7.58 /

-0.07 (-0.92%)

APLS Apellis
$59.71 /

-0.97 (-1.60%)

ALXN Alexion
$180.56 /

-1.34 (-0.74%)

Wednesday
Options
Gilead call volume above normal and directionally bullish » 14:25
06/16/21
06/16
14:25
06/16/21
14:25
GILD

Gilead

$67.68 /

-0.43 (-0.63%)

Bullish option flow…

Bullish option flow detected in Gilead with 15,976 calls trading, 1.1x expected, and implied vol increasing over 1 point to 20.42%. Jun-21 70 calls and Jul-21 70 calls are the most active options, with total volume in those strikes near 7,000 contracts. The Put/Call Ratio is 0.24. Earnings are expected on July 29th.

ShowHide Related Items >><<
GILD Gilead
$67.68 /

-0.43 (-0.63%)

GILD Gilead
$67.68 /

-0.43 (-0.63%)

06/16/21 Roth Capital
JTX-1811 IND-clearance further validates Jounce platform, says Roth Capital
06/15/21 Piper Sandler
Jounce Therapeutics receives $25M milestone from Gilead, says Piper Sandler
04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
GILD Gilead
$67.68 /

-0.43 (-0.63%)

GILD Gilead
$67.68 /

-0.43 (-0.63%)

GILD Gilead
$67.68 /

-0.43 (-0.63%)

GILD Gilead
$67.68 /

-0.43 (-0.63%)

Recommendations
JTX-1811 IND-clearance further validates Jounce platform, says Roth Capital » 13:58
06/16/21
06/16
13:58
06/16/21
13:58
JNCE

Jounce Therapeutics

$7.41 /

-0.11 (-1.46%)

, GILD

Gilead

$68.57 /

+0.46 (+0.68%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah notes that Jounce Therapeutics (JNCE) announced IND-clearance for JTX-1811, its CCR8 antibody licensed to Gilead (GILD), and per the agreement, this milestone triggers a $25M payment to Jounce. Gilead will now also assume all future development associated with the program, and Jounce is eligible to receive an additional $660M in milestone payments plus royalties. The analyst believes that JTX-1811 has significant potential in immuno-oncology, further validating Jounce's immunooncology platform, and looks forward to hearing more at the company's Virtual R&D day on June 23rd. Jallah has a Buy rating and a price target of $15 on Jounce's shares.

ShowHide Related Items >><<
JNCE Jounce Therapeutics
$7.41 /

-0.11 (-1.46%)

GILD Gilead
$68.57 /

+0.46 (+0.68%)

JNCE Jounce Therapeutics
$7.41 /

-0.11 (-1.46%)

06/15/21 Piper Sandler
Jounce Therapeutics receives $25M milestone from Gilead, says Piper Sandler
04/12/21 Roth Capital
Jounce reported 'very robust' JTX-8064 analysis, says Roth Capital
03/14/21 Piper Sandler
Jounce Therapeutics initiated with an Overweight at Piper Sandler
02/26/21 H.C. Wainwright
Jounce Therapeutics price target raised to $15 from $11 at H.C. Wainwright
GILD Gilead
$68.57 /

+0.46 (+0.68%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
JNCE Jounce Therapeutics
$7.41 /

-0.11 (-1.46%)

GILD Gilead
$68.57 /

+0.46 (+0.68%)

  • 10
    Mar
GILD Gilead
$68.57 /

+0.46 (+0.68%)

JNCE Jounce Therapeutics
$7.41 /

-0.11 (-1.46%)

GILD Gilead
$68.57 /

+0.46 (+0.68%)

GILD Gilead
$68.57 /

+0.46 (+0.68%)

Hot Stocks
North American rail traffic rose 15.3% in week ended June 12, AAR says » 13:26
06/16/21
06/16
13:26
06/16/21
13:26
CNI

Canadian National

$109.63 /

-0.59 (-0.54%)

, CP

Canadian Pacific

$79.44 /

-0.81 (-1.01%)

, CSX

CSX

$97.61 /

-0.83 (-0.84%)

, KSU

Kansas City Southern

$291.09 /

-1.075 (-0.37%)

, NSC

Norfolk Southern

$272.53 /

-0.74 (-0.27%)

, UNP

Union Pacific

$221.49 /

-1.28 (-0.57%)

, GWR

Genesee & Wyoming

$111.91 /

+ (+0.00%)

The Association of…

The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending June 12. For this week, total U.S. weekly rail traffic was 529,635 carloads and intermodal units, up 17.9% compared with the same week last year. Total carloads for the week ending June 12 were 241,628 carloads, up 21.8% compared with the same week in 2020, while U.S. weekly intermodal volume was 288,007 containers and trailers, up 14.8% compared to 2020. For some rail traffic categories, percentage changes for the current week compared with the same week in 2020 are inflated because of the widespread shutdowns - and subsequent large reduction in rail volumes - that impacted many economic sectors last year at this time. North American rail volume for the week ending June 12, on 12 reporting U.S., Canadian and Mexican railroads totaled 338,783 carloads, up 16.2% compared with the same week last year, and 377,780 intermodal units, up 14.5% compared with last year. Total combined weekly rail traffic in North America was 716,563 carloads and intermodal units, up 15.3% Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Genesee & Wyoming (GWR), Kansas City Southern (KSU), Norfolk Southern (NSC) and Union Pacific (UNP). Reference Link

ShowHide Related Items >><<
UNP Union Pacific
$221.49 /

-1.28 (-0.57%)

NSC Norfolk Southern
$272.53 /

-0.74 (-0.27%)

CSX CSX
$97.61 /

-0.83 (-0.84%)

CP Canadian Pacific
$79.44 /

-0.81 (-1.01%)

CNI Canadian National
$109.63 /

-0.59 (-0.54%)

CNI Canadian National
$109.63 /

-0.59 (-0.54%)

05/28/21 UBS
Canadian National upgraded to Buy from Neutral at UBS
05/28/21 Barclays
Kansas City Southern downgraded to Underweight from Equal Weight at Barclays
05/27/21 Scotiabank
Canadian Pacific price target raised to C$108 from C$96 at Scotiabank
05/27/21 Scotiabank
Canadian National upgraded to Outperform at Scotiabank after 12% pullback
CP Canadian Pacific
$79.44 /

-0.81 (-1.01%)

05/26/21 Desjardins
Canadian Pacific price target adjusted to reflect 5-for-1 split at Desjardins
05/25/21 Evercore ISI
Kansas City Southern resumed at In Line from Outperform at Evercore ISI
05/25/21 Evercore ISI
Canadian Pacific resumed with an In Line at Evercore ISI
CSX CSX
$97.61 /

-0.83 (-0.84%)

06/15/21 Deutsche Bank
CSX price target raised to $115 from $113 at Deutsche Bank
05/14/21 Stephens
Canadian rail that loses KCS likely to pursue an Eastern rail, says Stephens
04/21/21 Deutsche Bank
CSX price target raised to $113 from $105 at Deutsche Bank
04/21/21 RBC Capital
CSX price target raised to $108 from $100 at RBC Capital
KSU Kansas City Southern
$291.09 /

-1.075 (-0.37%)

NSC Norfolk Southern
$272.53 /

-0.74 (-0.27%)

05/04/21 Argus
Norfolk Southern price target raised to $310 from $275 at Argus
04/29/21 BMO Capital
Norfolk Southern price target raised to $285 from $250 at BMO Capital
04/29/21 Barclays
Norfolk Southern price target raised to $300 from $272 at Barclays
UNP Union Pacific
$221.49 /

-1.28 (-0.57%)

06/15/21 Deutsche Bank
Union Pacific price target raised to $256 from $252 at Deutsche Bank
05/28/21 Barclays
Union Pacific price target raised to $240 from $230 at Barclays
04/26/21 Deutsche Bank
Union Pacific price target raised to $252 from $239 at Deutsche Bank
04/23/21 RBC Capital
Union Pacific price target raised to $244 from $232 at RBC Capital
GWR Genesee & Wyoming
$111.91 /

+ (+0.00%)

UNP Union Pacific
$221.49 /

-1.28 (-0.57%)

NSC Norfolk Southern
$272.53 /

-0.74 (-0.27%)

KSU Kansas City Southern
$291.09 /

-1.075 (-0.37%)

CSX CSX
$97.61 /

-0.83 (-0.84%)

CP Canadian Pacific
$79.44 /

-0.81 (-1.01%)

CNI Canadian National
$109.63 /

-0.59 (-0.54%)

UNP Union Pacific
$221.49 /

-1.28 (-0.57%)

CP Canadian Pacific
$79.44 /

-0.81 (-1.01%)

CNI Canadian National
$109.63 /

-0.59 (-0.54%)

CSX CSX
$97.61 /

-0.83 (-0.84%)

CNI Canadian National
$109.63 /

-0.59 (-0.54%)

UNP Union Pacific
$221.49 /

-1.28 (-0.57%)

KSU Kansas City Southern
$291.09 /

-1.075 (-0.37%)

CSX CSX
$97.61 /

-0.83 (-0.84%)

CP Canadian Pacific
$79.44 /

-0.81 (-1.01%)

CNI Canadian National
$109.63 /

-0.59 (-0.54%)

Conference/Events
European Hematology Association to hold virtual meeting » 04:55
06/16/21
06/16
04:55
06/16/21
04:55
APTO

Aptose Biosciences

$3.50 /

-0.21 (-5.66%)

, MBIO

Mustang Bio

$3.57 /

-0.115 (-3.13%)

, QURE

uniQure

$34.46 /

-0.43 (-1.23%)

, RIGL

Rigel Pharmaceuticals

$4.27 /

-0.1 (-2.29%)

, MGTA

Magenta Therapeutics

$11.38 /

+0.05 (+0.44%)

, MEIP

MEI Pharma

$3.10 /

-0.15 (-4.62%)

, CRIS

Curis

$7.61 /

-0.44 (-5.47%)

, XLRN

Acceleron

$128.63 /

-2.39 (-1.82%)

, EPZM

Epizyme

$8.79 /

-0.025 (-0.28%)

, INCY

Incyte

$82.69 /

+0.11 (+0.13%)

, ORTX

Orchard Therapeutics

$4.85 /

-0.19 (-3.77%)

, TGTX

TG Therapeutics

$37.42 /

-0.88 (-2.30%)

, EQ

Equillium

$6.05 /

+0.05 (+0.83%)

, JAZZ

Jazz Pharmaceuticals

$183.42 /

-2.7 (-1.45%)

, VRTX

Vertex Pharmaceuticals

$188.94 /

-5.87 (-3.01%)

, SGEN

Seagen

$153.20 /

-2.99 (-1.91%)

, IMRA

Imara

$8.26 /

-0.44 (-5.06%)

, GBT

Global Blood Therapeutics

$39.60 /

-0.65 (-1.61%)

, BGNE

BeiGene

$332.97 /

-9.75 (-2.84%)

, APLS

Apellis

$60.63 /

-4.27 (-6.58%)

, AGIO

Agios Pharmaceuticals

$58.23 /

+0.04 (+0.07%)

, FMTX

Forma Therapeutics

$24.13 /

-0.09 (-0.37%)

, KROS

Keros Therapeutics

$52.55 /

-0.455 (-0.86%)

, CYAD

Celyad

$5.44 /

+0.03 (+0.55%)

, ALXN

Alexion

$181.90 /

+0.25 (+0.14%)

EHA 2021 Virtual Congress…

EHA 2021 Virtual Congress to be held on June 9-17. Webcast Link

ShowHide Related Items >><<
XLRN Acceleron
$128.63 /

-2.39 (-1.82%)

VRTX Vertex Pharmaceuticals
$188.94 /

-5.87 (-3.01%)

TGTX TG Therapeutics
$37.42 /

-0.88 (-2.30%)

SGEN Seagen
$153.20 /

-2.99 (-1.91%)

RIGL Rigel Pharmaceuticals
$4.27 /

-0.1 (-2.29%)

QURE uniQure
$34.46 /

-0.43 (-1.23%)

ORTX Orchard Therapeutics
$4.85 /

-0.19 (-3.77%)

MGTA Magenta Therapeutics
$11.38 /

+0.05 (+0.44%)

MEIP MEI Pharma
$3.10 /

-0.15 (-4.62%)

MBIO Mustang Bio
$3.57 /

-0.115 (-3.13%)

KROS Keros Therapeutics
$52.55 /

-0.455 (-0.86%)

JAZZ Jazz Pharmaceuticals
$183.42 /

-2.7 (-1.45%)

INCY Incyte
$82.69 /

+0.11 (+0.13%)

IMRA Imara
$8.26 /

-0.44 (-5.06%)

GBT Global Blood Therapeutics
$39.60 /

-0.65 (-1.61%)

FMTX Forma Therapeutics
$24.13 /

-0.09 (-0.37%)

EQ Equillium
$6.05 /

+0.05 (+0.83%)

EPZM Epizyme
$8.79 /

-0.025 (-0.28%)

CYAD Celyad
$5.44 /

+0.03 (+0.55%)

CRIS Curis
$7.61 /

-0.44 (-5.47%)

BGNE BeiGene
$332.97 /

-9.75 (-2.84%)

APTO Aptose Biosciences
$3.50 /

-0.21 (-5.66%)

APLS Apellis
$60.63 /

-4.27 (-6.58%)

ALXN Alexion
$181.90 /

+0.25 (+0.14%)

AGIO Agios Pharmaceuticals
$58.23 /

+0.04 (+0.07%)

APTO Aptose Biosciences
$3.50 /

-0.21 (-5.66%)

02/22/21 JonesTrading
Aptose Biosciences resumed with a Buy at JonesTrading
10/19/20 Cantor Fitzgerald
Aptose Biosciences initiated with an Overweight at Cantor Fitzgerald
09/22/20 Alliance Global Partners
Aptose Biosciences initiated with a Buy at Alliance Global Partners
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
MBIO Mustang Bio
$3.57 /

-0.115 (-3.13%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
QURE uniQure
$34.46 /

-0.43 (-1.23%)

06/14/21 BTIG
uniQure initiated with a Buy at BTIG
05/20/21 UBS
uniQure initiated with a Neutral at UBS
05/19/21 H.C. Wainwright
uniQure price target raised to $90 from $80 at H.C. Wainwright
04/26/21 Chardan
Chardan sees 'stock momentum' for uniQure after clinical hold lift
RIGL Rigel Pharmaceuticals
$4.27 /

-0.1 (-2.29%)

06/11/21 BMO Capital
Rigel Pharmaceuticals coverage transferred at BMO Capital
05/12/21 Cantor Fitzgerald
Rigel rallying on Curis IRAK4 program data, says Cantor Fitzgerald
04/13/21 Piper Sandler
Rigel results in severe COVID-19 trial 'pretty dramatic,' says Piper Sandler
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
MGTA Magenta Therapeutics
$11.38 /

+0.05 (+0.44%)

06/14/21 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
05/18/21 B. Riley
Magenta Therapeutics initiated with a Buy, $21 target at B. Riley
05/17/21 B. Riley
Magenta Therapeutics initiated with a Buy at B. Riley
05/13/21 Mizuho
Magenta Therapeutics price target raised to $17 from $16 at Mizuho
MEIP MEI Pharma
$3.10 /

-0.15 (-4.62%)

04/26/21 Wells Fargo
MEI Pharma likely to expand scope of voruciclib development, says Wells Fargo
10/12/20 Brookline
MEI Pharma initiated with a Buy at Brookline
09/22/20 Alliance Global Partners
MEI Pharma initiated with a Buy at Alliance Global Partners
07/06/20 Truist
MEI Pharma price target lowered to $12 from $16 at SunTrust
CRIS Curis
$7.61 /

-0.44 (-5.47%)

05/13/21 B. Riley
Curis price target raised to $22 from $19 at B. Riley
05/13/21 Cantor Fitzgerald
Curis price target raised to $24 from $15 at Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Initial look from Curis EHA updates 'very positive,' says Cantor Fitzgerald
XLRN Acceleron
$128.63 /

-2.39 (-1.82%)

06/11/21 H.C. Wainwright
Acceleron results for Phase 2 BEYOND study 'impressive,' says H.C. Wainwright
05/19/21 Piper Sandler
Piper remains bullish on Acceleron after Phase 2 PULSAR OLE, SPECTRA updates
04/26/21 Credit Suisse
Acceleron assumed with an Outperform at Credit Suisse
03/23/21
Fly Intel: Top five analyst downgrades
EPZM Epizyme
$8.79 /

-0.025 (-0.28%)

05/07/21 SVB Leerink
Epizyme upgraded to Outperform from Market Perform at SVB Leerink
04/23/21 Cowen
Epizyme transferred with Outperform at Cowen
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
INCY Incyte
$82.69 /

+0.11 (+0.13%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
ORTX Orchard Therapeutics
$4.85 /

-0.19 (-3.77%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/02/21 JPMorgan
Orchard Therapeutics assumed with an Overweight at JPMorgan
03/01/21 Stifel
Orchard Therapeutics initiated with a Buy at Stifel
02/18/21 Goldman Sachs
Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs
TGTX TG Therapeutics
$37.42 /

-0.88 (-2.30%)

04/20/21
Fly Intel: Top five analyst initiations
04/20/21 Goldman Sachs
TG Therapeutics initiated with a Neutral at Goldman Sachs
04/19/21 Cantor Fitzgerald
TG Therapeutics price target raised to $74 from $68 at Cantor Fitzgerald
04/19/21 H.C. Wainwright
TG Therapeutics price target raised to $89 from $79 at H.C. Wainwright
EQ Equillium
$6.05 /

+0.05 (+0.83%)

03/03/21
Fly Intel: Top five analyst initiations
03/03/21 JonesTrading
Equillium initiated with a Buy at JonesTrading
11/30/20 H.C. Wainwright
Equillium price target lowered to $12 from $22 at H.C. Wainwright
07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
JAZZ Jazz Pharmaceuticals
$183.42 /

-2.7 (-1.45%)

05/19/21
Fly Intel: Top five analyst initiations
05/19/21 JPMorgan
Jazz Pharmaceuticals resumed with an Overweight at JPMorgan
05/17/21 H.C. Wainwright
Jazz Pharmaceuticals price target raised to $212 from $207 at H.C. Wainwright
04/21/21 Cantor Fitzgerald
Jazz Pharmaceuticals price target raised to $198 from $185 at Cantor Fitzgerald
VRTX Vertex Pharmaceuticals
$188.94 /

-5.87 (-3.01%)

06/14/21 Truist
Vertex Pharmaceuticals price target raised to $331 from $305 at Truist
06/14/21 SVB Leerink
Vertex Pharmaceuticals price target lowered to $200 from $250 at SVB Leerink
06/14/21 Deutsche Bank
Grifols upgraded to Buy from Hold at Deutsche Bank
06/13/21 Piper Sandler
Vertex Pharmaceuticals price target lowered to $261 from $347 at Piper Sandler
SGEN Seagen
$153.20 /

-2.99 (-1.91%)

05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
IMRA Imara
$8.26 /

-0.44 (-5.06%)

03/08/21 SVB Leerink
Imara price target lowered to $42 from $59 at SVB Leerink
01/06/21 SVB Leerink
Imara selloff a potential buying opportunity, says SVB Leerink
08/17/20
Fly Intel: Top five analyst upgrades
08/17/20 Citi
Imara upgraded to Buy from Neutral at Citi
GBT Global Blood Therapeutics
$39.60 /

-0.65 (-1.61%)

05/07/21 Cantor Fitzgerald
Global Blood Therapeutics price target lowered to $110 from $120 at Cantor Fitzgerald
05/06/21 Piper Sandler
Global Blood price target lowered to $45 from $50 at Piper Sandler
04/14/21
Fly Intel: Top five analyst initiations
04/14/21 SVB Leerink
SVB Leerink bullish on Global Blood Therapeutics, initiates with an Outperform
BGNE BeiGene
$332.97 /

-9.75 (-2.84%)

06/14/21 SVB Leerink
BeiGene price target raised to $417 from $388 at SVB Leerink
03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
APLS Apellis
$60.63 /

-4.27 (-6.58%)

05/20/21 UBS
Apellis initiated with a Buy at UBS
05/18/21 BMO Capital
Apellis price target raised to $68 from $64 at BMO Capital
05/17/21 Oppenheimer
Apellis price target raised to $67 from $64 at Oppenheimer
05/17/21 Raymond James
Apellis price target raised to $115 from $104 at Raymond James
AGIO Agios Pharmaceuticals
$58.23 /

+0.04 (+0.07%)

06/10/21 H.C. Wainwright
Agios Pharmaceuticals initiated with a Buy at H.C. Wainwright
04/30/21 Goldman Sachs
Agios Pharmaceuticals reinstated with a Neutral at Goldman Sachs
04/30/21 Barclays
Agios Pharmaceuticals price target raised to $70 from $65 at Barclays
03/30/21 Piper Sandler
Agios should rally on Forma Therapeutics data, says Piper Sandler
FMTX Forma Therapeutics
$24.13 /

-0.09 (-0.37%)

03/31/21 H.C. Wainwright
Forma Therapeutics price target raised to $55 from $53 at H.C. Wainwright
02/17/21
Fly Intel: Top five analyst initiations
02/17/21 Oppenheimer
Forma Therapeutics initiated with an Outperform at Oppenheimer
KROS Keros Therapeutics
$52.55 /

-0.455 (-0.86%)

12/08/20 SVB Leerink
Keros Therapeutics price target raised to $80 from $42 at SVB Leerink
12/08/20 H.C. Wainwright
Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright
12/08/20 Piper Sandler
Keros Therapeutics price target raised to $95 from $75 at Piper Sandler
11/18/20 Piper Sandler
Keros Therapeutics price target raised to $75 from $55 at Piper Sandler
CYAD Celyad
$5.44 /

+0.03 (+0.55%)

03/25/21 JonesTrading
Celyad downgraded to Hold from Buy at JonesTrading
12/08/20 H.C. Wainwright
Celyad price target lowered to $18 from $22 at H.C. Wainwright
ALXN Alexion
$181.90 /

+0.25 (+0.14%)

05/05/21
Fly Intel: Top five analyst upgrades
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
05/03/21 SVB Leerink
Alexion price target raised to $173 from $156 at SVB Leerink
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
XLRN Acceleron
$128.63 /

-2.39 (-1.82%)

VRTX Vertex Pharmaceuticals
$188.94 /

-5.87 (-3.01%)

TGTX TG Therapeutics
$37.42 /

-0.88 (-2.30%)

SGEN Seagen
$153.20 /

-2.99 (-1.91%)

RIGL Rigel Pharmaceuticals
$4.27 /

-0.1 (-2.29%)

QURE uniQure
$34.46 /

-0.43 (-1.23%)

ORTX Orchard Therapeutics
$4.85 /

-0.19 (-3.77%)

MGTA Magenta Therapeutics
$11.38 /

+0.05 (+0.44%)

MEIP MEI Pharma
$3.10 /

-0.15 (-4.62%)

MBIO Mustang Bio
$3.57 /

-0.115 (-3.13%)

KROS Keros Therapeutics
$52.55 /

-0.455 (-0.86%)

JAZZ Jazz Pharmaceuticals
$183.42 /

-2.7 (-1.45%)

INCY Incyte
$82.69 /

+0.11 (+0.13%)

IMRA Imara
$8.26 /

-0.44 (-5.06%)

GBT Global Blood Therapeutics
$39.60 /

-0.65 (-1.61%)

FMTX Forma Therapeutics
$24.13 /

-0.09 (-0.37%)

EQ Equillium
$6.05 /

+0.05 (+0.83%)

EPZM Epizyme
$8.79 /

-0.025 (-0.28%)

CRIS Curis
$7.61 /

-0.44 (-5.47%)

BGNE BeiGene
$332.97 /

-9.75 (-2.84%)

APTO Aptose Biosciences
$3.50 /

-0.21 (-5.66%)

APLS Apellis
$60.63 /

-4.27 (-6.58%)

ALXN Alexion
$181.90 /

+0.25 (+0.14%)

AGIO Agios Pharmaceuticals
$58.23 /

+0.04 (+0.07%)

  • 15
    Dec
  • 09
    Dec
  • 11
    Dec
  • 02
    Dec
  • 13
    Nov
  • 14
    Aug
  • 16
    Jul
  • 01
    Jul
  • 25
    Jun
  • 19
    Jun
VRTX Vertex Pharmaceuticals
$188.94 /

-5.87 (-3.01%)

RIGL Rigel Pharmaceuticals
$4.27 /

-0.1 (-2.29%)

ORTX Orchard Therapeutics
$4.85 /

-0.19 (-3.77%)

JAZZ Jazz Pharmaceuticals
$183.42 /

-2.7 (-1.45%)

INCY Incyte
$82.69 /

+0.11 (+0.13%)

EPZM Epizyme
$8.79 /

-0.025 (-0.28%)

VRTX Vertex Pharmaceuticals
$188.94 /

-5.87 (-3.01%)

TGTX TG Therapeutics
$37.42 /

-0.88 (-2.30%)

SGEN Seagen
$153.20 /

-2.99 (-1.91%)

QURE uniQure
$34.46 /

-0.43 (-1.23%)

MBIO Mustang Bio
$3.57 /

-0.115 (-3.13%)

JAZZ Jazz Pharmaceuticals
$183.42 /

-2.7 (-1.45%)

INCY Incyte
$82.69 /

+0.11 (+0.13%)

IMRA Imara
$8.26 /

-0.44 (-5.06%)

GBT Global Blood Therapeutics
$39.60 /

-0.65 (-1.61%)

EQ Equillium
$6.05 /

+0.05 (+0.83%)

CRIS Curis
$7.61 /

-0.44 (-5.47%)

APTO Aptose Biosciences
$3.50 /

-0.21 (-5.66%)

APLS Apellis
$60.63 /

-4.27 (-6.58%)

ALXN Alexion
$181.90 /

+0.25 (+0.14%)

VRTX Vertex Pharmaceuticals
$188.94 /

-5.87 (-3.01%)

INCY Incyte
$82.69 /

+0.11 (+0.13%)

FMTX Forma Therapeutics
$24.13 /

-0.09 (-0.37%)

EQ Equillium
$6.05 /

+0.05 (+0.83%)

CRIS Curis
$7.61 /

-0.44 (-5.47%)

APLS Apellis
$60.63 /

-4.27 (-6.58%)

ALXN Alexion
$181.90 /

+0.25 (+0.14%)

Tuesday
Recommendations
Jounce Therapeutics receives $25M milestone from Gilead, says Piper Sandler » 12:22
06/15/21
06/15
12:22
06/15/21
12:22
JNCE

Jounce Therapeutics

$7.84 /

+0.87 (+12.48%)

, GILD

Gilead

$67.89 /

-0.26 (-0.38%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating and $20 price target on Jounce Therapeutics (JNCE), which will receive a $25M milestone from partner Gilead (GILD) for IND clearance for anti-CCR8 antibody GS-1811. Jounce, which expects to initiate eight expansion cohorts in 2H21, now holds pro forma cash of roughly $296M to advance its innovative I-O pipeline, Tenthoff tells investors in a research note.

ShowHide Related Items >><<
JNCE Jounce Therapeutics
$7.84 /

+0.87 (+12.48%)

GILD Gilead
$67.89 /

-0.26 (-0.38%)

JNCE Jounce Therapeutics
$7.84 /

+0.87 (+12.48%)

04/12/21 Roth Capital
Jounce reported 'very robust' JTX-8064 analysis, says Roth Capital
03/14/21 Piper Sandler
Jounce Therapeutics initiated with an Overweight at Piper Sandler
02/26/21 H.C. Wainwright
Jounce Therapeutics price target raised to $15 from $11 at H.C. Wainwright
12/04/20 H.C. Wainwright
Jounce Therapeutics assumed with a Buy at H.C. Wainwright
GILD Gilead
$67.89 /

-0.26 (-0.38%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
JNCE Jounce Therapeutics
$7.84 /

+0.87 (+12.48%)

GILD Gilead
$67.89 /

-0.26 (-0.38%)

  • 10
    Mar
GILD Gilead
$67.89 /

-0.26 (-0.38%)

JNCE Jounce Therapeutics
$7.84 /

+0.87 (+12.48%)

GILD Gilead
$67.89 /

-0.26 (-0.38%)

GILD Gilead
$67.89 /

-0.26 (-0.38%)

Hot Stocks
Canadian Pacific: SMART-TD urges STB to reject CN's proposed use of voting trust » 08:33
06/15/21
06/15
08:33
06/15/21
08:33
CP

Canadian Pacific

$80.61 /

+0.37 (+0.46%)

, CNI

Canadian National

$111.05 /

+0.72 (+0.65%)

, KSU

Kansas City Southern

$292.28 /

-1.645 (-0.56%)

Canadian Pacific Railway…

Canadian Pacific Railway (CP) announced that SMART-Transportation Division, North America's largest railroad operating union, has submitted a letter urging the Surface Transportation Board to reject Canadian National's (CNI) proposed use of a voting trust. SMART-TD joins a growing list of shippers, communities, labor unions and other stakeholders who have voiced opposition to CN's voting trust as part of its proposal to combine with Kansas City Southern (KSU). In a letter to the STB, SMART-TD President Jeremy Ferguson writes: "The approval of the CN voting trust by the STB would be risky for the railway industry and quite possibly will negatively impact our involved SMART-TD members. Approval of the CN voting trust proposal would harm employees of both KCS and CN due to the amount of debt CN will carry and the real possibility that the CN transaction would fail the regulatory test in the end. The CN/KCS transaction is the opposite of an end-to-end merger and would be anti-competitive due to the overlap of existing rail lines and affected customers. The CN already has a high capacity mainline route from Chicago, IL straight to New Orleans, LA, therefore with CN acquiring KCS there would be no need for parallel routes such as the KCS line from Kansas City through to New Orleans. If the CN voting trust and proposed merger were granted approval, we fully expect significant job losses on either CN or KCS because ultimately the transaction would require either a sale or abandonment of duplicative rail lines. The consequences for SMART-TD members would be uncertain, adverse, and certainly contrary to the public interest." In contrast, the SMART-TD letter says of Canadian Pacific's proposed combination with KCS: "we anticipate growth in both rail businesses and jobs for SMART-TD members."

ShowHide Related Items >><<
CP Canadian Pacific
$80.61 /

+0.37 (+0.46%)

CNI Canadian National
$111.05 /

+0.72 (+0.65%)

CP Canadian Pacific
$80.61 /

+0.37 (+0.46%)

05/27/21 Scotiabank
Canadian Pacific price target raised to C$108 from C$96 at Scotiabank
05/26/21 Desjardins
Canadian Pacific price target adjusted to reflect 5-for-1 split at Desjardins
05/25/21 Evercore ISI
Kansas City Southern resumed at In Line from Outperform at Evercore ISI
05/25/21 Evercore ISI
Canadian Pacific resumed with an In Line at Evercore ISI
CNI Canadian National
$111.05 /

+0.72 (+0.65%)

05/28/21 UBS
Canadian National upgraded to Buy from Neutral at UBS
05/28/21 Barclays
Kansas City Southern downgraded to Underweight from Equal Weight at Barclays
05/27/21 Scotiabank
Canadian National upgraded to Outperform at Scotiabank after 12% pullback
KSU Kansas City Southern
$292.28 /

-1.645 (-0.56%)

KSU Kansas City Southern
$292.28 /

-1.645 (-0.56%)

CP Canadian Pacific
$80.61 /

+0.37 (+0.46%)

CNI Canadian National
$111.05 /

+0.72 (+0.65%)

CP Canadian Pacific
$80.61 /

+0.37 (+0.46%)

CNI Canadian National
$111.05 /

+0.72 (+0.65%)

CP Canadian Pacific
$80.61 /

+0.37 (+0.46%)

KSU Kansas City Southern
$292.28 /

-1.645 (-0.56%)

CP Canadian Pacific
$80.61 /

+0.37 (+0.46%)

CNI Canadian National
$111.05 /

+0.72 (+0.65%)

Hot Stocks
Jounce Therapeutics achieves first milestone in license agreement with Gilead » 08:04
06/15/21
06/15
08:04
06/15/21
08:04
JNCE

Jounce Therapeutics

$6.98 /

-0.07 (-0.99%)

, GILD

Gilead

$68.15 /

+0.09 (+0.13%)

Jounce Therapeutics…

Jounce Therapeutics (JNCE) announced the Food and Drug Administration's clearance of its Investigational New Drug application for JTX-1811, an anti-CCR8 antibody, for which Gilead Sciences (GILD) has exclusive rights to develop and commercialize. The IND clearance triggers a $25M milestone payment to Jounce. Under the terms of the September 2020 agreement, Gilead invested $35M in Jounce's common stock and made an $85M upfront payment to Jounce. Jounce has led the development of JTX-1811 through IND clearance, after which Gilead now has the sole right to develop and commercialize the program. After receiving this $25M milestone payment, Jounce may receive up to an additional $660M in future clinical, regulatory and commercial milestone payments and will also be eligible to receive royalties ranging from high single digit to mid-teens based upon worldwide sales. Any milestone or royalty paid to Jounce is subject to certain reductions as described in the license agreement.

ShowHide Related Items >><<
JNCE Jounce Therapeutics
$6.98 /

-0.07 (-0.99%)

GILD Gilead
$68.15 /

+0.09 (+0.13%)

JNCE Jounce Therapeutics
$6.98 /

-0.07 (-0.99%)

04/12/21 Roth Capital
Jounce reported 'very robust' JTX-8064 analysis, says Roth Capital
03/14/21 Piper Sandler
Jounce Therapeutics initiated with an Overweight at Piper Sandler
02/26/21 H.C. Wainwright
Jounce Therapeutics price target raised to $15 from $11 at H.C. Wainwright
12/04/20 H.C. Wainwright
Jounce Therapeutics assumed with a Buy at H.C. Wainwright
GILD Gilead
$68.15 /

+0.09 (+0.13%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
JNCE Jounce Therapeutics
$6.98 /

-0.07 (-0.99%)

GILD Gilead
$68.15 /

+0.09 (+0.13%)

  • 10
    Mar
GILD Gilead
$68.15 /

+0.09 (+0.13%)

JNCE Jounce Therapeutics
$6.98 /

-0.07 (-0.99%)

GILD Gilead
$68.15 /

+0.09 (+0.13%)

GILD Gilead
$68.15 /

+0.09 (+0.13%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.